RNFL loss tied to slower reaction times

Article

Glaucomatous structural damage may affect an individual's ability to divide attention when performing daily tasks such as driving, according to research recently published online.

Glaucomatous structural damage may affect an individual's ability to divide attention when performing daily tasks such as driving, according to research recently published online.

Researchers at the Hamilton Glaucoma Center, University of California San Diego, USA, conducted a cross-sectional observational study of 158 subjects from the Diagnostic Innovations in Glaucoma Study: 82 subjects with glaucoma and 76 controls of similar age.

The researchers measured the subjects’ reaction times to peripheral stimuli at low, medium, or high contrast while the subjects performed simulated driving tasks such as negotiating a curve or following another car.

They discovered that the glaucoma subjects' mean reaction times to the low contrast stimulus were 1.19 seconds for car following and 1.05 seconds for curve negotiation. The control subjects’ reaction times were 0.77 seconds and 0.64 seconds, respectively, for the two tasks.

A non-linear relationship was found between reaction times and the retinal nerve fibre layer thickness (RNFL) in the subjects’ better eye. After the researchers adjusted for factors such as age, cognitive ability and standard automated perimetry deviation in the better eye, RNFL thickness still remained significantly associated with reaction times.

"Information from structural tests may improve our ability to determine which patients are likely to have problems performing daily activities, such as driving," the researchers concluded.

To read an abstract of the study visit the American Journal of Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.